mavrakanas t - Search Results

Year	Number of Results
2000	1
2002	1
2008	1
2009	5
2010	3
2011	1
2012	2
2013	2
2014	3
2015	5
2016	3
2017	6
2018	7
2019	5
2020	8
2021	11
2022	10
2023	13
2024	14
2025	11

1

Effects of Glucagon-Like Peptide 1 Receptor Agonist Initiation in Patients With Heart Failure With Reduced Ejection Fraction and Implantable Cardiac Devices.

Marques P, Travlos CK, Matias P, Neves JS, Tsoukas MA, Mavrakanas TA, Joza J, Ferreira JP, Sharma A. Marques P, et al. Among authors: mavrakanas ta. JACC Heart Fail. 2025 Nov;13(11):102573. doi: 10.1016/j.jchf.2025.102573. Epub 2025 Sep 23. JACC Heart Fail. 2025. PMID: 40992090

2

Population Pharmacokinetic Modeling of Canagliflozin in Advanced Chronic Kidney Disease.

Elenjickal EJ, Mavrakanas TA, Gritsas A, Suri RS, Marsot A. Elenjickal EJ, et al. Among authors: mavrakanas ta. Clin Pharmacokinet. 2025 Sep 15. doi: 10.1007/s40262-025-01571-8. Online ahead of print. Clin Pharmacokinet. 2025. PMID: 40952584

3

Point-of-Care Ultrasonography and Worsening of Renal Function in Acute Heart Failure: A Cohort Study.

Soret G, Leidi A, Leszek A, Marti C, Carballo S, Stirnemann J, Grosgurin O, Reny JL, Mavrakanas TA. Soret G, et al. Among authors: mavrakanas ta. Can J Kidney Health Dis. 2025 Jul 29;12:20543581251328069. doi: 10.1177/20543581251328069. eCollection 2025. Can J Kidney Health Dis. 2025. PMID: 40756447 Free PMC article.

4

Aldosterone Breakthrough for the Prediction of Treatment Response to Mineralocorticoid Receptor Antagonists.

Imcaoudene AR, Najjar C, Marques P, Tsoukas MA, Sharma A, Mavrakanas TA. Imcaoudene AR, et al. Among authors: mavrakanas ta. Kidney Med. 2025 May 30;7(8):101040. doi: 10.1016/j.xkme.2025.101040. eCollection 2025 Aug. Kidney Med. 2025. PMID: 40740724 Free PMC article. No abstract available.

5

Impact of GLP-1 receptor agonist-based therapies on cardiovascular and renal outcomes in diabetic and non-diabetic patients with CKD.

Siniukovich A, Travlos CK, Freedman S, Mavrakanas TA, Gariani K. Siniukovich A, et al. Among authors: mavrakanas ta. Diabetol Metab Syndr. 2025 Jul 2;17(1):247. doi: 10.1186/s13098-025-01831-4. Diabetol Metab Syndr. 2025. PMID: 40605083 Free PMC article. Review.

6

Systematic Review on the Management of Diuretic Resistance in Acute Heart Failure across the Spectrum of Kidney Disease.

Marques P, Blydt-Hansen M, Takano T, Ferreira JP, Tsoukas MA, Sharma A, Mavrakanas TA. Marques P, et al. Among authors: mavrakanas ta. Cardiorenal Med. 2025;15(1):462-483. doi: 10.1159/000546520. Epub 2025 May 28. Cardiorenal Med. 2025. PMID: 40435978 Free PMC article.

7

Erythropoietic response to oral iron with sodium-glucose co-transporter 2 inhibitors.

Marques P, Matias P, Travlos CK, Angélico-Gonçalves A, Diniz H, Vasques-Nóvoa F, Packer M, Friões F, Tsoukas MA, Mavrakanas TA, Sharma A, Ferreira JP. Marques P, et al. Among authors: mavrakanas ta. Clin Res Cardiol. 2025 May 27. doi: 10.1007/s00392-025-02685-6. Online ahead of print. Clin Res Cardiol. 2025. PMID: 40425751

8

SGLT2 Inhibitors and Risk for Hyperkalemia Among Individuals Receiving RAAS Inhibitors.

Wing S, Ray JG, Yau K, Jeyakumar N, Abdullah S, Luo B, Cherney DZI, Harel Z, Hundemer GL, Mavrakanas TA, Molnar AO, Odutayo A, Perl J, Young A, Charytan D, Weir M, Wald R. Wing S, et al. Among authors: mavrakanas ta. JAMA Intern Med. 2025 Jul 1;185(7):827-836. doi: 10.1001/jamainternmed.2025.0686. JAMA Intern Med. 2025. PMID: 40293730

9

Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with and without Advanced CKD: Systematic Review and Meta-Analysis.

Elenjickal EJ, Travlos CK, Luu J, Lemay S, Suri RS, Mavrakanas TA. Elenjickal EJ, et al. Among authors: mavrakanas ta. Clin J Am Soc Nephrol. 2025 Mar 26;20(6):788-809. doi: 10.2215/CJN.0000000693. Clin J Am Soc Nephrol. 2025. PMID: 40137838

10

Prediction models for ischemic stroke and bleeding in dialysis patients: a systematic review and meta-analysis.

Travlos CK, Chirgwin-Dasgupta A, Trinh E, Sniderman AD, Alam A, Mavrakanas TA. Travlos CK, et al. Among authors: mavrakanas ta. Clin Kidney J. 2024 Nov 15;17(12):sfae347. doi: 10.1093/ckj/sfae347. eCollection 2024 Dec. Clin Kidney J. 2024. PMID: 39981320 Free PMC article.

11

Population Pharmacokinetic Modelling of Apixaban in End-Stage Kidney Disease Patients with Atrial Fibrillation Receiving Haemodialysis.

Konecki C, Lipman ML, Mavrakanas TA, Djerada Z. Konecki C, et al. Among authors: mavrakanas ta. Clin Pharmacokinet. 2025 Feb;64(2):307-321. doi: 10.1007/s40262-025-01476-6. Epub 2025 Jan 24. Clin Pharmacokinet. 2025. PMID: 39853633 Clinical Trial.

12

Role of SGLT-2 Inhibitors in Ultrafiltration Failure in Peritoneal Dialysis: A Narrative Review.

Riedl Khursigara M, Liu P, Kaur R, Mavrakanas TA. Riedl Khursigara M, et al. Among authors: mavrakanas ta. Can J Kidney Health Dis. 2024 Nov 5;11:20543581241293500. doi: 10.1177/20543581241293500. eCollection 2024. Can J Kidney Health Dis. 2024. PMID: 39502166 Free PMC article. Review.

13

Anticoagulation for Patients with Atrial Fibrillation Receiving Dialysis: A Pilot Randomized Controlled Trial.

Harel Z, Smyth B, Badve SV, Blum D, Beaubien-Souligny W, Silver SA, Clark E, Suri R, Mavrakanas TA, Sasal J, Prasad B, Eikelboom J, Tennankore K, Rigatto C, Prce I, Madore F, Mac-Way F, Steele A, Zeng Y, Sholzberg M, Dorian P, Yan AT, Sood MM, Gladstone DJ, Tseng E, Kitchlu A, Walsh M, Sapir D, Oliver MJ, Krishnan M, Kiaii M, Wong N, Kotwal S, Battistella M, Acedillo R, Lok C, Weir M, Wald R. Harel Z, et al. Among authors: mavrakanas ta. J Am Soc Nephrol. 2025 May 1;36(5):901-910. doi: 10.1681/ASN.0000000000000495. Epub 2024 Nov 4. J Am Soc Nephrol. 2025. PMID: 39495569

14

Influence of iron deficiency definition on the efficacy of intravenous iron in heart failure: a meta-analysis of randomized trials.

Marques P, Vasques-Nóvoa F, Matias P, Vieira JT, Mavrakanas TA, Sharma A, Friões F, Ferreira JP. Marques P, et al. Among authors: mavrakanas ta. Clin Res Cardiol. 2024 Oct 21. doi: 10.1007/s00392-024-02557-5. Online ahead of print. Clin Res Cardiol. 2024. PMID: 39432015

15

Canagliflozin Pharmacokinetics at Steady State in Patients on Maintenance Hemodialysis.

Mavrakanas TA, Marsot A, Tsirella E, Rios N, Gritsas A, Suri RS. Mavrakanas TA, et al. Kidney Int Rep. 2024 Aug 8;9(10):3049-3052. doi: 10.1016/j.ekir.2024.07.038. eCollection 2024 Oct. Kidney Int Rep. 2024. PMID: 39430196 Free PMC article. No abstract available.

16

Cardiovascular phenotypes in type 2 diabetes: Latent class analysis of the CANVAS Program and CREDENCE trial.

Razaghizad A, Ni J, Marques P, Mavrakanas TA, Tsoukas MA, Possik E, Huynh T, Edwards JD, Liu P, Swardfager W, Baroz F, Ferreira JP, Sharma A. Razaghizad A, et al. Among authors: mavrakanas ta. Diabetes Obes Metab. 2024 Nov;26(11):5025-5035. doi: 10.1111/dom.15768. Epub 2024 Sep 20. Diabetes Obes Metab. 2024. PMID: 39301712 Clinical Trial.

17

Meta-analysis evaluating apixaban in patients with atrial fibrillation and end-stage renal disease requiring dialysis.

AlTurki A, Marafi M, Dawas A, Joza J, Proietti R, Russo V, Mavrakanas T, Trinh E, Weber C, Suri R, Essebag V, Huynh T. AlTurki A, et al. Among authors: mavrakanas t. J Arrhythm. 2024 May 6;40(3):440-447. doi: 10.1002/joa3.13051. eCollection 2024 Jun. J Arrhythm. 2024. PMID: 38939758 Free PMC article.

18

Utilizing synchronous care to improve cardiovascular and renal health among patients with type 2 diabetes: Proof-of-concept results from the DECIDE-CV clinical programme.

Marques P, Mavrakanas TA, Guida J, Gédéon T, Emami A, Alaamiri A, Ho D, Possik E, Zhang G, Tsoukas MA, Sharma A. Marques P, et al. Among authors: mavrakanas ta. Diabetes Obes Metab. 2024 Aug;26(8):3448-3457. doi: 10.1111/dom.15691. Epub 2024 Jun 3. Diabetes Obes Metab. 2024. PMID: 38831564

19

Oral Anticoagulation Use in Individuals With Atrial Fibrillation and Chronic Kidney Disease: A Review.

Wing SL, Mavrakanas TA, Harel Z. Wing SL, et al. Among authors: mavrakanas ta. Semin Nephrol. 2024 Mar;44(2):151517. doi: 10.1016/j.semnephrol.2024.151517. Epub 2024 May 14. Semin Nephrol. 2024. PMID: 38744617 Free article. Review.

20

Medication Deprescribing in Patients Receiving Hemodialysis: A Prospective Controlled Quality Improvement Study.

Bortolussi-Courval É, Podymow T, Battistella M, Trinh E, Mavrakanas TA, McCarthy L, Moryousef J, Hanula R, Huon JF, Suri R, Lee TC, McDonald EG. Bortolussi-Courval É, et al. Among authors: mavrakanas ta. Kidney Med. 2024 Mar 20;6(5):100810. doi: 10.1016/j.xkme.2024.100810. eCollection 2024 May. Kidney Med. 2024. PMID: 38628463 Free PMC article.

21

Clinical Outcomes of Renin-Angiotensin-Aldosterone Blockade in Patients With Advanced Chronic Kidney Disease: A Systematic Review and Meta-analysis.

Vendeville N, Lepage MA, Festa MC, Mavrakanas TA. Vendeville N, et al. Among authors: mavrakanas ta. Can J Cardiol. 2024 Sep;40(9):1718-1728. doi: 10.1016/j.cjca.2024.02.027. Epub 2024 Mar 6. Can J Cardiol. 2024. PMID: 38458564 Free article.

22

Factor XI Inhibitors: Potential Role in End-Stage Kidney Disease.

Ades M, Simard C, Vanassche T, Verhamme P, Eikelboom J, Mavrakanas TA. Ades M, et al. Among authors: mavrakanas ta. Semin Nephrol. 2023 Nov;43(6):151484. doi: 10.1016/j.semnephrol.2023.151484. Epub 2024 Jan 24. Semin Nephrol. 2023. PMID: 38272779 Review.

23

Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials.

Tobe SW, Mavrakanas TA, Bajaj HS, Levin A, Tangri N, Slee A, Neuen BL, Perkovic V, Mahaffey KW, Rapattoni W, Ang FG. Tobe SW, et al. Among authors: mavrakanas ta. Diabetes Care. 2024 Mar 1;47(3):501-507. doi: 10.2337/dc23-1450. Diabetes Care. 2024. PMID: 38252809 Free PMC article.

24

Direct oral anticoagulants: the safer choice in chronic kidney disease?

Mavrakanas TA. Mavrakanas TA. Clin Kidney J. 2023 Nov 20;17(1):sfad288. doi: 10.1093/ckj/sfad288. eCollection 2024 Jan. Clin Kidney J. 2023. PMID: 38186881 Free PMC article. No abstract available.

25

Volume Status Assessment by Lung Ultrasound in End-Stage Kidney Disease: A Systematic Review.

Kharat A, Tallaa F, Lepage MA, Trinh E, Suri RS, Mavrakanas TA. Kharat A, et al. Among authors: mavrakanas ta. Can J Kidney Health Dis. 2023 Dec 25;10:20543581231217853. doi: 10.1177/20543581231217853. eCollection 2023. Can J Kidney Health Dis. 2023. PMID: 38148768 Free PMC article. Review.

26

Anticoagulation in Patients with Chronic Kidney Disease.

Elenjickal EJ, Travlos CK, Marques P, Mavrakanas TA. Elenjickal EJ, et al. Among authors: mavrakanas ta. Am J Nephrol. 2024;55(2):146-164. doi: 10.1159/000535546. Epub 2023 Nov 30. Am J Nephrol. 2024. PMID: 38035566 Free PMC article. Review.

27

The Association of Ejection Fraction With Hospital-Associated Cardiac Arrest and Heart Failure Hospitalization Differs According to Baseline Estimated GFR.

Ravi KS, Mavrakanas TA, Charytan DM, Mc Causland FR. Ravi KS, et al. Among authors: mavrakanas ta. Kidney Int Rep. 2023 Aug 25;8(11):2326-2332. doi: 10.1016/j.ekir.2023.08.030. eCollection 2023 Nov. Kidney Int Rep. 2023. PMID: 38025227 Free PMC article.

28

Early Discontinuation of Aspirin Among Patients with Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention with a Drug-Eluting Stent: A Meta-Analysis.

Festa MC, Rasasingam S, Sharma A, Mavrakanas TA. Festa MC, et al. Among authors: mavrakanas ta. Kidney360. 2023 Sep 1;4(9):e1245-e1256. doi: 10.34067/KID.0000000000000223. Epub 2023 Aug 1. Kidney360. 2023. PMID: 37768893 Free PMC article.

29

SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis.

Mavrakanas TA, Tsoukas MA, Brophy JM, Sharma A, Gariani K. Mavrakanas TA, et al. Sci Rep. 2023 Sep 23;13(1):15922. doi: 10.1038/s41598-023-42989-z. Sci Rep. 2023. PMID: 37741858 Free PMC article.

30

Erythropoietic response after intravenous iron in patients with heart failure and reduced ejection fraction with and without background treatment with sodium-glucose cotransporter 2 inhibitors.

Marques P, Matias P, Packer M, Vieira JT, Vasques-Nóvoa F, Sharma A, Mavrakanas TA, Friões F, Ferreira JP. Marques P, et al. Among authors: mavrakanas ta. Eur J Heart Fail. 2023 Dec;25(12):2191-2198. doi: 10.1002/ejhf.2992. Epub 2023 Aug 24. Eur J Heart Fail. 2023. PMID: 37559543 Free article.

31

Bioimpedance-Guided Monitoring of Volume Status in Patients With Kidney Disease: A Systematic Review and Meta-Analysis.

Horowitz L, Karadjian O, Braam B, Mavrakanas T, Weber C. Horowitz L, et al. Among authors: mavrakanas t. Can J Kidney Health Dis. 2023 Jul 11;10:20543581231185433. doi: 10.1177/20543581231185433. eCollection 2023. Can J Kidney Health Dis. 2023. PMID: 37457623 Free PMC article.

32

Electronic Decision Support for Deprescribing in Patients on Hemodialysis: Clinical Research Protocol for a Prospective, Controlled, Quality Improvement Study.

Bortolussi-Courval É, Podymow T, Trinh E, Moryousef J, Hanula R, Huon JF, Mavrakanas T, Suri R, Lee TC, McDonald EG. Bortolussi-Courval É, et al. Among authors: mavrakanas t. Can J Kidney Health Dis. 2023 Jun 26;10:20543581231165712. doi: 10.1177/20543581231165712. eCollection 2023. Can J Kidney Health Dis. 2023. PMID: 37435299 Free PMC article.

33

The impact of transsphenoidal surgery on pituitary function in patients with non-functioning macroadenomas.

Mavromati M, Mavrakanas T, Jornayvaz FR, Schaller K, Fitsiori A, Vargas MI, Lobrinus JA, Merkler D, Egervari K, Philippe J, Leboulleux S, Momjian S. Mavromati M, et al. Among authors: mavrakanas t. Endocrine. 2023 Aug;81(2):340-348. doi: 10.1007/s12020-023-03400-z. Epub 2023 May 24. Endocrine. 2023. PMID: 37222882 Free PMC article. Review.

34

Apixaban for stroke prevention in hemodialysis patients with nonvalvular atrial fibrillation.

Mavrakanas TA. Mavrakanas TA. Kidney Int. 2023 Jun;103(6):1014-1017. doi: 10.1016/j.kint.2023.03.027. Epub 2023 Apr 12. Kidney Int. 2023. PMID: 37059362 No abstract available.

35

Apixaban versus No Anticoagulation by P2Y12 Inhibitor Prescription Status in Dialysis Patients with Atrial Fibrillation.

Mavrakanas TA, Charytan DM. Mavrakanas TA, et al. Kidney360. 2022 Aug 1;3(10):1769-1771. doi: 10.34067/KID.0003002022. eCollection 2022 Oct 27. Kidney360. 2022. PMID: 36514740 Free PMC article.

36

Sodium-glucose co-transporter 2 inhibitors in patients with chronic kidney disease.

Solomon J, Festa MC, Chatzizisis YS, Samanta R, Suri RS, Mavrakanas TA. Solomon J, et al. Among authors: mavrakanas ta. Pharmacol Ther. 2023 Feb;242:108330. doi: 10.1016/j.pharmthera.2022.108330. Epub 2022 Dec 10. Pharmacol Ther. 2023. PMID: 36513134 Review.

37

Synchronous Health Care Delivery for the Optimization of Cardiovascular and Renal Care in Patients with Type 2 Diabetes.

Alqahtani M, Ganni E, Mavrakanas T, Tsoukas M, Peters T, Suri R, Fantus IG, Pavilanis A, Guida J, Razaghizad A, Sharma A. Alqahtani M, et al. Among authors: mavrakanas t. Curr Cardiol Rep. 2022 Aug;24(8):979-985. doi: 10.1007/s11886-022-01715-3. Epub 2022 Jun 25. Curr Cardiol Rep. 2022. PMID: 35751834 Review.

38

Hydralazine-Isosorbide Dinitrate Use in Patients With End-Stage Kidney Disease on Dialysis.

Mavrakanas TA, Soomro QH, Charytan DM. Mavrakanas TA, et al. Kidney Int Rep. 2022 Apr 6;7(6):1332-1340. doi: 10.1016/j.ekir.2022.03.032. eCollection 2022 Jun. Kidney Int Rep. 2022. PMID: 35685328 Free PMC article.

39

Clinical Prediction Models for Heart Failure Hospitalization in Type 2 Diabetes: A Systematic Review and Meta-Analysis.

Razaghizad A, Oulousian E, Randhawa VK, Ferreira JP, Brophy JM, Greene SJ, Guida J, Felker GM, Fudim M, Tsoukas M, Peters TM, Mavrakanas TA, Giannetti N, Ezekowitz J, Sharma A. Razaghizad A, et al. Among authors: mavrakanas ta. J Am Heart Assoc. 2022 May 17;11(10):e024833. doi: 10.1161/JAHA.121.024833. Epub 2022 May 16. J Am Heart Assoc. 2022. PMID: 35574959 Free PMC article.

40

Can Peer Review Be Kinder? Supportive Peer Review: A Re-Commitment to Kindness and a Call to Action.

Clase CM, Dicks E, Holden R, Sood MM, Levin A, Kalantar-Zadeh K, Moore LW, Bartlett SJ, Bello AK, Bohm C, Bridgewater D, Bouchard J, Burger D, Carrero JJ, Donald M, Elliott M, Goldenberg MJ, Jardine M, Lam NN, Maddigan WJ, Madore F, Mavrakanas TA, Molnar AO, Prasad GVR, Rigatto C, Tennankore KK, Torban E, Trainor L, White CA, Hartwig S. Clase CM, et al. Among authors: mavrakanas ta. Can J Kidney Health Dis. 2022 May 1;9:20543581221080327. doi: 10.1177/20543581221080327. eCollection 2022. Can J Kidney Health Dis. 2022. PMID: 35514878 Free PMC article.

41

Treatment Options for Venous Thromboembolism in Patients Receiving Dialysis.

Mavrakanas TA. Mavrakanas TA. Clin J Am Soc Nephrol. 2022 May;17(5):623-625. doi: 10.2215/CJN.03410322. Epub 2022 Apr 25. Clin J Am Soc Nephrol. 2022. PMID: 35470213 Free PMC article. No abstract available.

42

Should Oral Anticoagulation Be Used in ESKD Patients on Hemodialysis with Atrial Fibrillation?: COMMENTARY.

Mavrakanas TA. Mavrakanas TA. Kidney360. 2021 Apr 9;2(9):1412-1414. doi: 10.34067/KID.0001372021. eCollection 2021 Sep 30. Kidney360. 2021. PMID: 35378030 Free PMC article. No abstract available.

43

Outcomes with revascularization and medical therapy in patients with coronary disease and chronic kidney disease: A meta-analysis.

Leszek A, Poli L, Zbinden S, Godoy LC, Reny JL, Farkouh ME, Charytan DM, Mavrakanas TA. Leszek A, et al. Among authors: mavrakanas ta. Atherosclerosis. 2022 Jun;351:41-48. doi: 10.1016/j.atherosclerosis.2022.02.023. Epub 2022 Mar 4. Atherosclerosis. 2022. PMID: 35287949 Free article.

44

Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis: a clinical practice guideline.

Zeng L, Walsh M, Guyatt GH, Siemieniuk RAC, Collister D, Booth M, Brown P, Farrar L, Farrar M, Firth T, Fussner LA, Kilian K, Little MA, Mavrakanas TA, Mustafa RA, Piram M, Stamp LK, Xiao Y, Lytvyn L, Agoritsas T, Vandvik PO, Mahr A. Zeng L, et al. Among authors: mavrakanas ta. BMJ. 2022 Feb 25;376:e064597. doi: 10.1136/bmj-2021-064597. BMJ. 2022. PMID: 35217581

45

Management and outcomes of patients on maintenance dialysis during the first and second wave of the COVID-19 pandemic in Geneva, Switzerland.

Zamberg I, Mavrakanas T, Ernandez T, Bourquin V, Zellweger M, Marangon N, Raimbault F, Winzeler R, Iten A, Hammer N, Ponte B, Carballo S, Martin PY, Saudan P. Zamberg I, et al. Among authors: mavrakanas t. Swiss Med Wkly. 2021 Aug 27;151(33-34). doi: 10.4414/SMW.2021.w30006. Swiss Med Wkly. 2021. PMID: 34495598 Free article. Review.

46

Clinical Phenotypes in Patients With Type 2 Diabetes Mellitus: Characteristics, Cardiovascular Outcomes and Treatment Strategies.

Gouda P, Zheng S, Peters T, Fudim M, Randhawa VK, Ezekowitz J, Mavrakanas TA, Giannetti N, Tsoukas M, Lopes R, Sharma A. Gouda P, et al. Among authors: mavrakanas ta. Curr Heart Fail Rep. 2021 Oct;18(5):253-263. doi: 10.1007/s11897-021-00527-w. Epub 2021 Aug 24. Curr Heart Fail Rep. 2021. PMID: 34427881 Review.

47

Correction to: Acute kidney injury with partial Fanconi syndrome in a patient with leptospirosis: a case report.

Weiner M, Coen M, Serratrice J, Mavrakanas TA, Leidi A. Weiner M, et al. Among authors: mavrakanas ta. J Med Case Rep. 2021 Aug 16;15(1):434. doi: 10.1186/s13256-021-03040-9. J Med Case Rep. 2021. PMID: 34399837 Free PMC article. No abstract available.

48

Perioperative Evolution of Sodium Levels in Cirrhotic Patients Undergoing Liver Transplantation: An Observational Cohort and Literature Review.

Zamberg I, Maillard J, Assouline B, Tomala S, Keli-Barcelos G, Aldenkortt F, Mavrakanas T, Andres A, Schiffer E. Zamberg I, et al. Among authors: mavrakanas t. Hepat Med. 2021 Aug 7;13:71-82. doi: 10.2147/HMER.S320127. eCollection 2021. Hepat Med. 2021. PMID: 34393524 Free PMC article.

49

Acute kidney injury with partial Fanconi syndrome in a patient with leptospirosis: a case report.

Weiner M, Coen M, Serratrice J, Mavrakanas TA, Leidi A. Weiner M, et al. Among authors: mavrakanas ta. J Med Case Rep. 2021 Jul 23;15(1):358. doi: 10.1186/s13256-021-02978-0. J Med Case Rep. 2021. PMID: 34294111 Free PMC article.

50

Epidemiology, thrombolytic management, and outcomes of acute stroke among patients with chronic kidney disease: a systematic review and meta-analysis.

Zamberg I, Assouline-Reinmann M, Carrera E, Sood MM, Sozio SM, Martin PY, Mavrakanas TA. Zamberg I, et al. Among authors: mavrakanas ta. Nephrol Dial Transplant. 2022 Jun 23;37(7):1289-1301. doi: 10.1093/ndt/gfab197. Nephrol Dial Transplant. 2022. PMID: 34100934

51

Prasugrel and Ticagrelor in Patients with Drug-Eluting Stents and Kidney Failure.

Mavrakanas TA, Kamal O, Charytan DM. Mavrakanas TA, et al. Clin J Am Soc Nephrol. 2021 May 8;16(5):757-764. doi: 10.2215/CJN.12120720. Epub 2021 Apr 2. Clin J Am Soc Nephrol. 2021. PMID: 33811128 Free PMC article.

52

[Oral anticoagulation in chronic kidney disease].

Barrelet I, Mavrakanas T, Carballo S. Barrelet I, et al. Among authors: mavrakanas t. Rev Med Suisse. 2021 Jan 20;17(722):142-145. Rev Med Suisse. 2021. PMID: 33470571 French.

53

[Internal medicine in 2020].

Darbellay Farhoumand P, Berner A, Leszek A, Novotny-Court F, Koegler F, Mavrakanas T, Leidi A, Lister K, Carballo S, Reny JL. Darbellay Farhoumand P, et al. Among authors: mavrakanas t. Rev Med Suisse. 2021 Jan 20;17(722):124-129. Rev Med Suisse. 2021. PMID: 33470568 Review. French.

54

A Systematic Review of the Incidence of Arrhythmias in Hemodialysis Patients Undergoing Long-Term Monitoring With Implantable Loop Recorders.

Roberts PR, Stromberg K, Johnson LC, Wiles BM, Mavrakanas TA, Charytan DM. Roberts PR, et al. Among authors: mavrakanas ta. Kidney Int Rep. 2020 Nov 2;6(1):56-65. doi: 10.1016/j.ekir.2020.10.020. eCollection 2021 Jan. Kidney Int Rep. 2020. PMID: 33426385 Free PMC article.

55

Mineralocorticoid receptor antagonists in patients with chronic kidney disease.

Cosimato C, Agoritsas T, Mavrakanas TA. Cosimato C, et al. Among authors: mavrakanas ta. Pharmacol Ther. 2021 Mar;219:107701. doi: 10.1016/j.pharmthera.2020.107701. Epub 2020 Oct 4. Pharmacol Ther. 2021. PMID: 33027644 Free article. Review.

56

Cobalt alloy hip prostheses and new-onset heart failure in patients with and without chronic kidney disease.

Mavrakanas TA, Kamal O, Charytan DM. Mavrakanas TA, et al. Clin Nephrol. 2020 Oct;94(4):215-216. doi: 10.5414/CN110031. Clin Nephrol. 2020. PMID: 32893814 No abstract available.

57

Direct oral anticoagulants in chronic kidney disease: an update.

Mavrakanas TA, Charytan DM, Winkelmayer WC. Mavrakanas TA, et al. Curr Opin Nephrol Hypertens. 2020 Sep;29(5):489-496. doi: 10.1097/MNH.0000000000000634. Curr Opin Nephrol Hypertens. 2020. PMID: 32740218 Free PMC article. Review.

58

Apixaban versus No Anticoagulation in Patients Undergoing Long-Term Dialysis with Incident Atrial Fibrillation.

Mavrakanas TA, Garlo K, Charytan DM. Mavrakanas TA, et al. Clin J Am Soc Nephrol. 2020 Aug 7;15(8):1146-1154. doi: 10.2215/CJN.11650919. Epub 2020 May 22. Clin J Am Soc Nephrol. 2020. PMID: 32444398 Free PMC article.

59

Risk of Cardiovascular Events and Mortality Among Elderly Patients With Reduced GFR Receiving Direct Oral Anticoagulants.

Ashley J, McArthur E, Bota S, Harel Z, Battistella M, Molnar AO, Jun M, Badve SV, Garg AX, Manuel D, Tanuseputro P, Wells P, Mavrakanas T, Rhodes E, Sood MM. Ashley J, et al. Among authors: mavrakanas t. Am J Kidney Dis. 2020 Sep;76(3):311-320. doi: 10.1053/j.ajkd.2020.02.446. Epub 2020 Apr 22. Am J Kidney Dis. 2020. PMID: 32333946

60

Mineralocorticoid Receptor Antagonists and Renal Outcomes in Heart Failure Patients with and without Chronic Kidney Disease.

Mavrakanas TA, Giannetti N, Sapir-Pichhadze R, Alam A. Mavrakanas TA, et al. Cardiorenal Med. 2020;10(1):32-41. doi: 10.1159/000503223. Epub 2019 Oct 30. Cardiorenal Med. 2020. PMID: 31665724

61

Response to the Letter to the Editor From Dr Kawada, "Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors for the Treatment of Hypertensive Patients With Type 2 Diabetes Mellitus".

Mavrakanas TA, Lipman ML. Mavrakanas TA, et al. Can J Diabetes. 2020 Feb;44(1):5. doi: 10.1016/j.jcjd.2019.08.004. Epub 2019 Aug 15. Can J Diabetes. 2020. PMID: 31582207 No abstract available.

62

Association of Chronic Kidney Disease with Preserved Ejection Fraction Heart Failure Is Independent of Baseline Cardiac Function.

Mavrakanas TA, Khattak A, Wang W, Singh K, Charytan DM. Mavrakanas TA, et al. Kidney Blood Press Res. 2019;44(5):1247-1258. doi: 10.1159/000502874. Epub 2019 Sep 2. Kidney Blood Press Res. 2019. PMID: 31476759 Free article.

63

Duration of Dual Antiplatelet Therapy in Patients with CKD and Drug-Eluting Stents: A Meta-Analysis.

Mavrakanas TA, Chatzizisis YS, Gariani K, Kereiakes DJ, Gargiulo G, Helft G, Gilard M, Feres F, Costa RA, Morice MC, Georges JL, Valgimigli M, Bhatt DL, Mauri L, Charytan DM. Mavrakanas TA, et al. Clin J Am Soc Nephrol. 2019 Jun 7;14(6):810-822. doi: 10.2215/CJN.12901018. Epub 2019 Apr 22. Clin J Am Soc Nephrol. 2019. PMID: 31010936 Free PMC article.

64

External validation of prediction models for mortality in an incident dialysis population .

Mavrakanas TA, Asfour K, Vasilevsky M, Barré PE, Alam A. Mavrakanas TA, et al. Clin Nephrol. 2019 Feb;91(2):65-71. doi: 10.5414/CN109310. Clin Nephrol. 2019. PMID: 30526813

65

Echocardiographic parameters and renal outcomes in patients with preserved renal function, and mild- moderate CKD.

Mavrakanas TA, Khattak A, Singh K, Charytan DM. Mavrakanas TA, et al. BMC Nephrol. 2018 Jul 11;19(1):176. doi: 10.1186/s12882-018-0975-5. BMC Nephrol. 2018. PMID: 29996910 Free PMC article.

66

Direct Factor Xa Inhibitors for Long-term Stroke Prevention in Atrial Fibrillation: Could the Lower Dose Fit All?

Mavrakanas TA, Sood MM. Mavrakanas TA, et al. Can J Cardiol. 2018 May;34(5):690.e15. doi: 10.1016/j.cjca.2018.02.003. Epub 2018 Feb 7. Can J Cardiol. 2018. PMID: 29731031 No abstract available.

67

Angiotensin-Converting Enzyme Inhibitors vs. Angiotensin Receptor Blockers for the Treatment of Hypertension in Adults With Type 2 Diabetes: Why We Favour Angiotensin Receptor Blockers.

Mavrakanas TA, Lipman ML. Mavrakanas TA, et al. Can J Diabetes. 2018 Apr;42(2):118-123. doi: 10.1016/j.jcjd.2017.11.006. Epub 2017 Dec 22. Can J Diabetes. 2018. PMID: 29602404 Review.

68

[Recent advances in internal medicine].

Von Düring S, Mavrakanas T, Muller H, Primmaz S, Grosgurin O, Louis Simonet M, Marti C, Nendaz M, Serratrice J, Stirnemann J, Carballo S, Darbellay Farhoumand P. Von Düring S, et al. Among authors: mavrakanas t. Rev Med Suisse. 2018 Jan 17;14(590):140-144. Rev Med Suisse. 2018. PMID: 29341527 French.

69

The Impact of Intradialytic Pedaling Exercise on Arterial Stiffness: A Pilot Randomized Controlled Trial in a Hemodialysis Population.

Cooke AB, Ta V, Iqbal S, Gomez YH, Mavrakanas T, Barré P, Vasilevsky M, Rahme E, Daskalopoulou SS. Cooke AB, et al. Among authors: mavrakanas t. Am J Hypertens. 2018 Mar 10;31(4):458-466. doi: 10.1093/ajh/hpx191. Am J Hypertens. 2018. PMID: 29126178 Clinical Trial.

70

Early versus late initiation of renal replacement therapy in patients with acute kidney injury: a meta-analysis of randomised clinical trials.

Mavrakanas TA, Aurian-Blajeni DE, Charytan DM. Mavrakanas TA, et al. Swiss Med Wkly. 2017 Oct 12;147:w14507. doi: 10.4414/smw.2017.14507. eCollection 2017. Swiss Med Wkly. 2017. PMID: 29039628 Free article.

71

Epidemiology and Natural History of the Cardiorenal Syndromes in a Cohort with Echocardiography.

Mavrakanas TA, Khattak A, Singh K, Charytan DM. Mavrakanas TA, et al. Clin J Am Soc Nephrol. 2017 Oct 6;12(10):1624-1633. doi: 10.2215/CJN.04020417. Epub 2017 Aug 11. Clin J Am Soc Nephrol. 2017. PMID: 28801528 Free PMC article.

72

Neutropenia in kidney and liver transplant recipients: Risk factors and outcomes.

Mavrakanas TA, Fournier MA, Clairoux S, Amiel JA, Tremblay ME, Vinh DC, Coursol C, Thirion DJG, Cantarovich M. Mavrakanas TA, et al. Clin Transplant. 2017 Oct;31(10). doi: 10.1111/ctr.13058. Epub 2017 Aug 12. Clin Transplant. 2017. PMID: 28736953 Clinical Trial.

73

Platelet reactivity in stable cardiovascular patients with chronic kidney disease.

Mavrakanas TA, Alam A, Reny JL, Fontana P. Mavrakanas TA, et al. Platelets. 2018 Jul;29(5):455-462. doi: 10.1080/09537104.2017.1316485. Epub 2017 Jun 5. Platelets. 2018. PMID: 28580812 Free article.

74

Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients.

Mavrakanas TA, Samer CF, Nessim SJ, Frisch G, Lipman ML. Mavrakanas TA, et al. J Am Soc Nephrol. 2017 Jul;28(7):2241-2248. doi: 10.1681/ASN.2016090980. Epub 2017 Mar 16. J Am Soc Nephrol. 2017. PMID: 28302754 Free PMC article.

75

Cardiovascular complications in chronic dialysis patients.

Mavrakanas TA, Charytan DM. Mavrakanas TA, et al. Curr Opin Nephrol Hypertens. 2016 Nov;25(6):536-544. doi: 10.1097/MNH.0000000000000280. Curr Opin Nephrol Hypertens. 2016. PMID: 27636771 Free PMC article. Review.

76

Serial versus single troponin measurements for the prediction of cardiovascular events and mortality in stable chronic haemodialysis patients.

Mavrakanas TA, Sniderman AD, Barré PE, Alam A. Mavrakanas TA, et al. Nephrology (Carlton). 2018 Jan;23(1):69-74. doi: 10.1111/nep.12945. Nephrology (Carlton). 2018. PMID: 27718506

77

High Ultrafiltration Rates Increase Troponin Levels in Stable Hemodialysis Patients.

Mavrakanas TA, Sniderman AD, Barré PE, Vasilevsky M, Alam A. Mavrakanas TA, et al. Am J Nephrol. 2016;43(3):173-8. doi: 10.1159/000445360. Epub 2016 Apr 12. Am J Nephrol. 2016. PMID: 27064739

78

Is diabetes mellitus a risk factor for venous thromboembolism? A systematic review and meta-analysis of case-control and cohort studies.

Gariani K, Mavrakanas T, Combescure C, Perrier A, Marti C. Gariani K, et al. Among authors: mavrakanas t. Eur J Intern Med. 2016 Mar;28:52-8. doi: 10.1016/j.ejim.2015.10.001. Epub 2015 Oct 23. Eur J Intern Med. 2016. PMID: 26507303

79

Bivalirudin in ST-segment-elevation myocardial infarction: for better or worse?

Mavrakanas TA, Chatzizisis YS. Mavrakanas TA, et al. Expert Rev Cardiovasc Ther. 2015;13(8):893-5. doi: 10.1586/14779072.2015.1064311. Epub 2015 Jul 2. Expert Rev Cardiovasc Ther. 2015. PMID: 26138859

80

Bivalirudin in stable angina and acute coronary syndromes.

Mavrakanas TA, Chatzizisis YS. Mavrakanas TA, et al. Pharmacol Ther. 2015 Aug;152:1-10. doi: 10.1016/j.pharmthera.2015.04.003. Epub 2015 Apr 7. Pharmacol Ther. 2015. PMID: 25857452 Review.

81

Direct oral anticoagulants: efficacy and safety in patient subgroups.

Mavrakanas TA, Samer C, Fontana P, Perrier A. Mavrakanas TA, et al. Swiss Med Wkly. 2015 Feb 6;145:w14081. doi: 10.4414/smw.2015.14081. eCollection 2015. Swiss Med Wkly. 2015. PMID: 25658756 Free article. Review.

82

Endogenous endophthalmitis in a patient with diabetes and foot osteomyelitis.

Mavrakanas TA, de Haller R, Philippe J. Mavrakanas TA, et al. Can J Diabetes. 2015 Feb;39(1):18-20. doi: 10.1016/j.jcjd.2014.05.011. Epub 2014 Oct 22. Can J Diabetes. 2015. PMID: 25444679

83

[A review of hospital based internal medicine in 2013].

Carballo S, Lucker L, Mavrakanas T, John G, Felix P, Perrier A. Carballo S, et al. Among authors: mavrakanas t. Rev Med Suisse. 2014 Jan 22;10(414):171-2, 174-6. Rev Med Suisse. 2014. PMID: 24624734 Review. French.

84

Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.

Mavrakanas TA, Gariani K, Martin PY. Mavrakanas TA, et al. Eur J Intern Med. 2014 Feb;25(2):173-6. doi: 10.1016/j.ejim.2013.11.007. Epub 2013 Dec 4. Eur J Intern Med. 2014. PMID: 24315413

85

Carbimazole-induced, ANCA-associated, crescentic glomerulonephritis: case report and literature review.

Mavrakanas TA, Bouatou Y, Samer C, de Seigneux S, Meyer P. Mavrakanas TA, et al. Ren Fail. 2013;35(3):414-7. doi: 10.3109/0886022X.2012.760356. Epub 2013 Jan 24. Ren Fail. 2013. PMID: 23343442 Free article. Review.

86

Severe mitral valve regurgitation in polymyositis.

Mavrakanas TA, Lobrinus A, Berdagué P, Seebach JD, Reny JL. Mavrakanas TA, et al. J Clin Rheumatol. 2012 Oct;18(7):367-9. doi: 10.1097/RHU.0b013e31826d1e2c. J Clin Rheumatol. 2012. PMID: 23047538 Review. No abstract available.

87

Low dose pioglitazone does not affect bone formation and resorption markers or bone mineral density in streptozocin-induced diabetic rats.

Tsirella E, Mavrakanas T, Rager O, Tsartsalis S, Kallaras K, Kokkas B, Mironidou-Tzouveleki M. Tsirella E, et al. Among authors: mavrakanas t. J Physiol Pharmacol. 2012 Apr;63(2):201-4. J Physiol Pharmacol. 2012. PMID: 22653908 Free article.

88

The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism.

Mavrakanas T, Bounameaux H. Mavrakanas T, et al. Pharmacol Ther. 2011 Apr;130(1):46-58. doi: 10.1016/j.pharmthera.2010.12.007. Epub 2010 Dec 24. Pharmacol Ther. 2011. PMID: 21185864 Review.

89

Effect of ramipril alone compared to ramipril with eplerenone on diabetic nephropathy in streptozocin-induced diabetic rats.

Mavrakanas TA, Cheva A, Kallaras K, Karkavelas G, Mironidou-Tzouveleki M. Mavrakanas TA, et al. Pharmacology. 2010;86(2):85-91. doi: 10.1159/000316113. Epub 2010 Aug 6. Pharmacology. 2010. PMID: 20689340

90

A prospective study of acute poisonings in a sample of Greek patients.

Exiara T, Mavrakanas TA, Papazoglou L, Papazoglou D, Christakidis D, Maltezos E. Exiara T, et al. Among authors: mavrakanas ta. Cent Eur J Public Health. 2009 Sep;17(3):158-60. doi: 10.21101/cejph.a3522. Cent Eur J Public Health. 2009. PMID: 20020606 Free article.

91

Transient glycosuria during a urinary tract infection.

Mavrakanas TA, Tomos C, Pratsiou P, Seventekidou I, Tzouvelekis G. Mavrakanas TA, et al. Presse Med. 2010 Jan;39(1):145-6. doi: 10.1016/j.lpm.2009.09.002. Epub 2009 Oct 21. Presse Med. 2010. PMID: 19846272 No abstract available.

92

Childhood obesity and elevated blood pressure in a rural population of northern Greece.

Mavrakanas TA, Konsoula G, Patsonis I, Merkouris BP. Mavrakanas TA, et al. Rural Remote Health. 2009 Apr-Jun;9(2):1150. Epub 2009 Jun 25. Rural Remote Health. 2009. PMID: 19555129 Free article.

93

C-peptide and chronic complications in patients with type-2 diabetes and the metabolic syndrome.

Mavrakanas T, Frachebois C, Soualah A, Aloui F, Julier I, Bastide D. Mavrakanas T, et al. Presse Med. 2009 Oct;38(10):1399-403. doi: 10.1016/j.lpm.2009.02.023. Epub 2009 May 5. Presse Med. 2009. PMID: 19419831

94

[C-peptide: a by-product of insulin biosynthesis or an active peptide hormone?].

Mavrakanas T, Bastide D. Mavrakanas T, et al. Presse Med. 2009 Jan;38(1):68-72. doi: 10.1016/j.lpm.2008.07.015. Epub 2008 Oct 31. Presse Med. 2009. PMID: 18951760 Review. French. No abstract available.

95

Prevalence of astigmatism among students in northern Greece.

Mandalos AT, Peios DK, Mavrakanas TA, Golias VA, Megalou KG, Delidou KA, Gregoriadou AC, Katsougiannopoulos BC. Mandalos AT, et al. Among authors: mavrakanas ta. Eur J Ophthalmol. 2002 Jan-Feb;12(1):1-4. doi: 10.1177/112067210201200101. Eur J Ophthalmol. 2002. PMID: 11936436

96

Prevalence of myopia in a sample of Greek students.

Mavrakanas TA, Mandalos A, Peios D, Golias V, Megalou K, Gregoriadou A, Delidou K, Katsougiannopoulos B. Mavrakanas TA, et al. Acta Ophthalmol Scand. 2000 Dec;78(6):656-9. doi: 10.1034/j.1600-0420.2000.078006656.x. Acta Ophthalmol Scand. 2000. PMID: 11167226 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

96 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

96 results

Results by year